Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Sponsor

Palo Alto Medical Foundation (Other)

Overall Status

Completed

CT.gov ID

NCT00002064

Collaborator

(none)

Location

Study Details

Study Description

Brief Summary

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition or Disease	Intervention/Treatment	Phase
Toxoplasmosis, Cerebral HIV Infections	Drug: Pyrimethamine Drug: Clindamycin	N/A

Study Design

Study Type:

Interventional

Primary Purpose:

Treatment

Official Title:

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 0 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.